Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
MERCK SHARP & DOHME LLC (MRK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/05/2011 |
BW
| Merck to Acquire Inspire Pharmaceuticals, Inc. |
| 04/01/2011 |
BW
| Merck to Hold First-Quarter 2011 Sales and Earnings Conference Call on April 29 |
| 03/31/2011 |
BW
| New Data Analyses with VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained Virologic Response |
| 03/31/2011 |
BW
| VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control |
| 03/24/2011 |
BW
| ADDING and REPLACING FDA Expands Indication for ZOSTAVAX®, Merck's Shingles Vaccine, to Include Adults Ages 50 to 59 |
| 03/24/2011 |
BW
| Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck |
| 03/22/2011 |
BW
| Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health |
| 03/18/2011 |
BW
| Committee for Medicinal Products for Human Use (CHMP) Issues Positive Opinion for New Contraception Offering, NOMAC-E2 |
| 03/15/2011 |
BW
| Merck to Present at Barclays Capital 2011 Global Healthcare Conference |
| 03/07/2011 |
BW
| Merck Announces New Data Analyses for VICTRELIS™ (Boceprevir) will be Presented at The International Liver CongressTM / 2011 EASL Annual Meeting |
| 03/01/2011 |
BW
| Merck's ISENTRESS® (raltegravir) Demonstrated Durable Reductions in HIV-1 Viral Load and Sustained Tolerability At Three Years of Treatment in Previously Untreated Adult Patients Infected with HIV-1 |
| 02/28/2011 |
BW
| Merck to Present at Citi 2011 Global Health Care Conference |
| 02/28/2011 |
BW
| Fujifilm to Acquire Merck Biomanufacturing Network |
| 02/22/2011 |
BW
| Merck Announces Second Quarter 2011 Dividend |
| 02/14/2011 |
BW
| Merck Wins First FOSAMAX® (alendronate sodium) State Court Trial |
| 12/14/2010 |
BW
| The PATH Malaria Vaccine Initiative, Merck and NYU Langone Medical Center Collaborate to Research Potential Malaria Vaccine |
| 12/07/2010 |
BW
| Merck Prices $2.0 Billion Debt Offering |
| 12/02/2010 |
BW
| Merck to Acquire SmartCells, Inc. |
| 11/30/2010 |
BW
| Merck Board Elects Kenneth C. Frazier as Next CEO; Richard T. Clark to Continue as Chairman |
| 11/29/2010 |
BW
| Merck Reports Initial Results of Phase III Study of ISENTRESS® (raltegravir) Investigational Once-Daily Dosing in Treatment-Naïve Adult Patients Infected with HIV-1 |
| 11/23/2010 |
BW
| Merck Announces First-Quarter 2011 Dividend |
| 11/17/2010 |
BW
| FDA Advisory Committee Supports Approval of GARDASIL® for Prevention of Anal Cancer and AIN in both Men and Women |
| 11/17/2010 |
BW
| In Phase III Study Merck's Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD |
| 11/09/2010 |
BW
| Merck Wins TEMODAR® Patent Infringement Lawsuit on Appeal |
| 10/18/2010 |
BW
| New Data on Odanacatib, Merck's Investigational Cathepsin-K Inhibitor for Osteoporosis, Presented at American Society for Bone and Mineral Research Annual Meeting |
| 10/12/2010 |
BW
| Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All Markets Outside of the United States, China and Japan |
| 10/12/2010 |
BW
| Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All Markets Outside of the United States, China and Japan |
| 10/01/2010 |
BW
| Merck Announces Pivotal Phase III Data for Boceprevir will be Presented at the American Association for the Study of Liver Diseases 2010 Annual Meeting |
| 10/01/2010 |
BW
| Merck to Hold Third-Quarter 2010 Sales and Earnings Conference Call on Oct. 29 |
| 09/29/2010 |
BW
| ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) Awarded Prix Galien USA 2010 Top Honor |
| 09/22/2010 |
BW
| Merck Significantly Expands its Patient Assistance Program Offerings to Provide Access to More Medicines for People in Need |
| 09/16/2010 |
BW
| Merck's Non-Profit to Advance Science Education Joins President Obama's Educate to Innovate Campaign |
| 08/24/2010 |
BW
| Merck Provides New Funding to Fight HIV/AIDS in Botswana |
| 08/12/2010 |
BW
| Merck Announces Mandatory Conversion of its 6.00% Mandatory Convertible Preferred Stock |
|
|
|